Anti-PD-1 Antibody

Anti-PD-1 Antibody

• Description: Mouse Monoclonal Antibody specific to PD-1
• Product Name Alternative: Protein PD-1, hPD-1, CD antigen CD279
• CAS Number: 9007-83-4
• Gene Name: PDCD1
• NCBI Gene ID: PDCD1
• UniProt: Q15116
• Cellular Locus: Cell membrane, Single-pass type I membrane protein.
• Host: Mouse
• Reactivity: Human
• Immunogen: Recombinant human PD-1.
• Target Antigen: Programmed cell death protein 1
• Target: PD-1
• Clonality: Monoclonal
• Isotype: IgG2b
• Type: Antibody
• Applications: IHC
• Field of Research: Cancer research
• Purification Method: Purified by immunoaffinity chromatography
• Concentration: Lot Specific
• Dilution: Dilute in PBS or medium that is identical to that used in the assay system.
• Format: Purified
• Form: Liquid
• Buffer: Tris
• Function: Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self (PubMed:21276005). Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 (PubMed:21276005). Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity). {UniProtKB:Q02242, PubMed:21276005}.; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28951311). The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed:28951311). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed:22658127, PubMed:25034862, PubMed:25399552). {PubMed:22658127, PubMed:25034862, PubMed:25399552, PubMed:28951311}.
• Additionnal Information:
  
  Immunohistochemistry: use at a dilution of 1:100-1:200 on formalin-fixed, paraffin-embedded samples after heat-induced epitope retrieval at pH 9 for 10-30 minutes.
• Storage Conditions: Store at 2-8°C. Do not freeze.
• Specificity: Human PD-1. Reactivity with other species has not been investigated.
• Formulation: Tris buffer, pH 7.3-7.7, 1% BSA, 0.1% sodium azide.
• Buffer pH: pH 7.3-7.7
• Target Background: Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and bcl-6, PD-1 is expressed by fewer B- cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small cell lung cancer, melanoma, and renal-cell cancer.